RIJ Plans World’s First Trial of iPS Cell Therapy in Men: President & CEO Kagimoto

July 16, 2012
At a recent monthly seminar held by the Japan Pharmaceutical Licensing Association (JPLA) in Tokyo, Hardy TS Kagimoto, president and CEO of Retina Institute Japan K.K. (RIJ), announced his company’s plan to initiate the world’s first global clinical trials of...read more